newsfilter
← Latest News
Business Wire·

Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

COYA
  • Coya Therapeutics announced financial results for the quarter ended September 30, 2026, & provided a corporate update.
  • The Phase 2/3 ALSTARS trial for COYA 302 in ALS patients achieved full enrollment with 137 participants, exceeding the planned 120.
  • Coya plans to initiate an open-label extension of the ALSTARS trial to allow participants to continue receiving COYA 302 after the 48-week study period.
  • Topline data from the 24-week double-blind treatment phase of the ALSTARS trial is expected in early Q2 2027.
  • Coya presented Neurofilament Light Chain biomarker stratification methodology at the 2026 Annual NEALS Meeting.
  • Preclinical results for COYA 303 were published in the International Journal of Molecular Sciences demonstrating immunomodulatory effects.
  • Cash & cash equivalents totaled $35.8 million as of September 30, 2026, sufficient to fund operations into the second half of 2027.
  • Research & development expenses increased to $8.6 million for the quarter ended September 30, 2026, from $2.9 million in the same period of 2025.
  • Collaboration revenue was $0.2 million for the three months ended September 30, 2026, compared to $3.6 million in the prior year period.
  • Net loss for the quarter ended September 30, 2026, was $10.6 million, compared to $2.1 million in the same period of 2025.
  • Coya expects to announce biomarker data from the completed frontotemporal dementia (FTD) investigator-initiated study in Q1 2027.
  • A Phase 2 study evaluating COYA 302 for FTD is scheduled to initiate in 2027.
  • COYA 302 is an investigational biologic combination therapy comprising low-dose interleukin-2 & CTLA-4 Ig intended to enhance regulatory T-cell function.
  • The ALSTARS trial is a randomized, multi-center, double-blind, placebo-controlled study evaluating COYA 302 efficacy & safety in ALS patients.